Intravascular large B-cell lymphoma(IVLBCL) is a rare form of diffuse LBCL characterized by preferential intravascular growth of malignant lymphocytes,aggressive behavior,and an often fatal course.It displays some differences in clinical presentation among diverse geographical areas.The immunophenotype plays a critical role in diagnosis and differential diagnosis.Recent therapeutic approaches,such as the rituximab plus CHOP regimen,could have a positive impact in IVLBCL patients.The use of high-dose chemotherapy supported by autologous stem-cell transplantation may improve current outcomes.

Cytokine-induced killer(CIK) cells are heterogeneous lymphocytes generated by incubation of human peripheral blood mononuclear cells with various cytokines in vitro,characterized by both the T lymphocyte's powerful cytotoxic activity and the natural killer(NK) cell's non-major histocompatibility-restricted antitumor activity in vitro and in vivo.CIK cells have their peculiar superiority over standard lymphokine activated killer(LAK) cells,tumor-infiltration lymphocytes(TIL) and anti-CD3 antibody induced activated killer(CD3AK) cells in application to the cancer adoptive immunotherapy and have hence received wide attention from researchers.This article updates recent researches on CIK cells,their interaction with dendritic cells,bispecific antibodies and oncolytic viruses,as well as their use in gene transfer.

Based on the practive of traditional allogeneic hematopoietic stem-cell transplantation therapy allo-HSCT and the development of nonmyeloablative conditioning, a new immunotherapy for solid tumor nonmyeloablative allo-HSCT, has been initiated. The nonmyeloablative,preparative regimens are associated with the use of lower dose of drugs,and less treatment-related toxicities. Instead of achieving maximal tumor reduction, the regimens are disigned to induce adequate immunosuppression to permit the engraftment of donor hematopoietic stem cells and serve as the platform for the administration of donor T cell in adoptive cell therapy. Donor's T-cell mediates a graft-versus-tumor(GVT)effect. This response is effective for the eradication of acceptor's tumor cell. This article reviews the concept, rationale, early clinical results, and limitation of nonmyeloablative allo-HSCT as a novel immunotherapy in solid tumors.

Human telomerase reverse transcriptase(hTERT),a catalytic subunit of telomerase,is highly expressed in a vast majority of cancer cells,but not in most normal adult cells,which makes it a broadly applicable molecular target for cancer immunotherapy.T cell epitope-based vaccines make use of T-cell epitopes from tumor antigens,and have its own unique advantages in cancer immunotherapy.The T-cell epitope peptide vaccine derived from hTERT can efficiently evoke specific cytotoxic T lymphocytes(CTL) responses,and has exhibited its anti-tumor effect in vivo in mice.Now it has already been put into experiment on human beings and displayed a good application prospect.

Chemotherapeutic drugs conventionally used for their cytotoxic activity can also exert their influence on the immune system by grooming the tumor microenvironment,abrogating immune tolerance and inciting immune reconstitution.Due to their immunomodulatory features,chemotherapeutics,used as a preconditioning regimen and combined with subsequent immunotherapy,can mobilize the immune system to generate antitumor immune response.The synergy between chemotherapy and immunotherapy has brought some enlightenment to the development of new protocols for cancer treatment.

The mechanism of carcinoma occurrence is of multiform. One of the scheduled multi modality treatment is hyperthermia. Result of research indicates that hyperthermia can kills the tumor cells by affecting carcinogens, tumor suppressors and immunity. This review presents the current knowledge of hyperthermia on mechanism of therapeutic effects and the application in the treatment.

Objective:To investigate the inhibitory effects of cytokine induced-killer(CIK) cells combined with docetaxel(DTX) on the expansion of lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo.Methods:Peripheral blood mononuclear cells(PBMC) from healthy donors were incubated in vitro to induce CIK cells in the presence of interferon-gamma(IFN-?),IL-2 and anti-CD3 monoclonal antibody.MTT assay was employed to evaluate the cytotoxic activity of DTX,CIK cells and their combination against SPC-A1/DTX cells in vitro.SPC-A1/DTX lung adenocarcinoma cells were injected subcutaneously into nude mice.On the 14 th day,normal saline(control group),docetaxel(DTX 1 mg/kg in 0.2 ml,DTX group),CIK cells(1?107,CIK group),and CIK cells combined with docetaxel(CIK+DTX group) were administered intraperitoneally respectively.All the nude mice were sacrificed at day 15 after treatment and the tumor were weighted out.Results:MTT assay showed that the IC50 to docetaxel in SPC-A1/DTX cells was 110.5 ?g/ml and 8.5 ?g/ml in wild SPC-A1 cells.CIK cells possessed a higher anti-tumor cytotoxic activity in SPC-A1/DTX cells in vitro than in wild SPC-A1 cells(P

s: Gastric carcinoma is the most common malignant tumor in China. When exposed to the same susceptible factor, different people have different incidence. Recent studies revealed that it may be related to some genes' polymorphism. In this article, the polymorphism of metabolism enzyme gene, oncogene, anti-oncogene, immune factor gene, pepsinogen C gene and mucin gene are reviewed. We highlight the situation of gastric carcinoma with some susceptible genetypes, also the possibility of using them to help scanning.

Objective To detect the methylation status of DLEC1 promoter in the tissue and serum of colorectal cancer(CRC) patients and to evaluate its clinical relevance.Methods Genomic DNA was extracted from the tissues(cancer tissue and corresponding adjacent normal tissue) and sera of 71 CRC patients;serum genomic DNA was also obtained from 20 patients with benign gastrointestinal diseases and 20 healthy donors.Promoter methylation status of DLEC1 gene was detected by methylation-specific polymerase chain reaction(MSP).Results The incidence of aberrant methylation of DLEC1 promoter was 45.1%(32/71) in CRC tissues,which was significantly higher than that in the adjacent normal tissues(7.1%,4/56)(P

Objective: To evaluate the clinical value of positron emission tomography/ computed tomography(PET/CT) with fluorine-18-labeled fluorodeoxyglucose(18F-FDG) in dectecting and diagnosing the recurrence and metastasis of colorectal cancer.Methods: The results of whole-body PET/CT of 68 patients with colorectal cancer were analyzed retrospectively.The average follow-up time was 15.8 months.The diagnosis of recurrence tumor and/or metastasis was based on pathologic examination,colonoscopy,multi-modality imaging and clinical follow-up.Results: Fifty-five of the 68 patients had recurrence and /or metastasis but no recurrence was found in the other 13 cases.The sensitivity,specificity and accuracy of PET/CT in detecting recurrent and metastatic tumor were 96.4%,76.9% and 92.6% respectively.PET/CT successfully detected one or several malignant insidious lesions in 8 cases with negative findings by CT and /or ultrasonography,and it revaeled more malignant lesions than CT and ultrasonography in 30.9%(17/55)of the patients.The clinical therapeutic strategies were changed in 11 case duo to the results of PET/CT,and the influence rate of PET/CT was 16.2%.The metastasis was mainly confined in the liver,lung,peritoneal cavity and retroperitoneal region.In the examination of the 24 patients with increased serum CEA,the positive rate of PET/CT was 91.7%.Conlusion: PET/CT can detect the recurrence and metastasis of colorectal cancer with high sensitivity and accuracy.